7 Cardiology Headlines You Missed in November 2025

November was a busy month for cardiology, between the US Food and Drug Administration’s (FDA) groundbreaking approval of plozasiran and the mountain of news presented at the American Heart Association’s Scientific Sessions 2025 in New Orleans, Louisiana. From olezarsen’s efficacy in severe hypertriglyceridemia to self-administered etripamil’s restoration of normal sinus rhythm in paroxysmal supraventricular tachycardia (PSVT), several major names in the cardiovascular pipeline made significant progress towards New Drug Application (NDA) submission last month.